Calcium Phosphate Statin Matrices for Bone Repair
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current bone grafting methods, particularly those using synthetic matrices, often fail to provide adequate compression resistance in high-load bearing areas, leading to integration issues and adverse tissue reactions, and are costly due to the use of expensive growth factors.
Innovation Solution
Development of implantable osteoconductive matrices comprising calcium phosphate particles with a therapeutically effective amount of statin, which can be directly injected into bone defects, providing a stable microenvironment for bone growth and allowing for faster healing with reduced manufacturing costs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Ease of manufacture
If synthetic matrices are used in bone grafting, then manufacturing cost is reduced, but compression resistance in high-load bearing areas is insufficient
Solution Approach 1:
The patent combines synthetic matrices with natural bone particles to create a composite graft material. The synthetic matrix provides cost-effectiveness and structural framework, while the natural bone particles contribute to compression resistance and load-bearing capacity in high-load areas, resolving the contradiction between manufacturing cost and compression resistance.
Solution Approach 2:
The patent applies different material compositions to different regions of the bone defect. High-load bearing areas receive particles with higher compression resistance properties, while other areas receive standard synthetic matrix, optimizing both cost and mechanical performance locally where needed.
2Productivity
If growth factors are used to spur bone formation, then bone healing is accelerated, but manufacturing cost increases
Solution Approach 1:
The patent uses naturally occurring bone particles and synthetic matrices that are cost-effective and biodegradable, replacing expensive growth factor preparations. These materials provide sufficient bone formation stimulation without the high cost associated with purified growth factors, achieving affordable accelerated healing.
Solution Approach 2:
The patent leverages the body's natural bone formation mechanisms and uses materials that promote self-organization and natural healing processes, rather than relying on expensive exogenous growth factors. The synthetic matrix and bone particles work together to stimulate endogenous bone regeneration at lower cost.
3Reliability
If spherical particles are added to matrix, then osseointegration is enhanced, but compression resistance in high load bearing areas is insufficient
Solution Approach 1:
The patent creates a composite structure combining spherical particles for osseointegration with elongated or irregularly shaped particles for compression resistance. This multi-particle composite approach allows simultaneous achievement of both osseointegration and compression resistance, overcoming the limitation of single-particle types.
Solution Approach 2:
The patent distributes different particle types to different locations within the bone defect. Spherical particles are placed in areas requiring osseointegration, while particles with higher compression resistance are positioned in high-load bearing areas, optimizing both functions spatially.
4Strength
If matrix is used in high load bearing areas, then structural support is provided, but matrix may dislodge and cause ischemic events
Solution Approach 1:
The patent uses a composite material system where the synthetic matrix provides structural support and the natural bone particles enhance mechanical strength and stability. This composite structure reduces the risk of matrix dislodgement in high-load bearing areas while maintaining structural support, thereby lowering ischemic event risk.
Solution Approach 2:
The patent incorporates particles with high compression resistance and appropriate particle size distribution that prevent matrix compaction and dislodgement before they can cause harm. The particle composition is designed in advance to maintain matrix stability under compression, preventing ischemic events before they occur.
Data Source
AI summary
Osteoconductive matrices and methods are provided that have one or more statins disposed in calcium phosphate particles. The matrices may be injected into a fracture site. The osteoconductive matrices provided allow for sustained release of the statin and facilitate bone formation and repair of the fracture site.